Background and Purpose: Smoothened (SMO) is a GPCR that mediates hedgehog signaling. Hedgehog binds the Patched, which in turn regulates SMO activation.
What is already known: Cyclopamine targets SMO as antagonist and fluorescentlylabelled cyclopamine has been used for fluorescence-based binding assays for SMO.
Structural analysis has suggested two binding sites on SMO, one in the receptor core and one the CRD.
What this study adds: We established a NanoBRET-based binding assay for SMO with superior sensitivity compared to fluorescence-based assays. This assay allows distinction of two separate binding sites for BODIPY-cyclopamine on SMO in live cells in real time.
What is the clinical significance: The assay is a valuable complement for drug discovery efforts and will support a better understanding of Class F GPCR pharmacology.
INTRODUCTION
Smoothened (SMO) is a G protein-coupled receptor (GPCR) which, alongside ten paralogues of Frizzleds (FZDs), forms the Class F of GPCRs (Schulte, 2010) . SMO signaling is of utmost importance during embryonic patterning and development, and dysfunction of SMO signaling is causative in the development of diverse tumors including basal cell carcinoma (Ingham & McMahon, 2001) . Therefore, pharmacological targeting of SMO and SMO signaling evolved as an attractive antitumor treatment strategy established in clinical practice (Wu, Zhang, Sun, McMahon & Wang, 2017) . On a structural level, this seven transmembrane domain spanning receptor is characterized by a large, extracellular cysteine-rich domain (CRD) and a long C-terminal domain (Schulte, 2010) . While SMO is essential for transmitting transcriptional responses via heterotrimeric G proteins and Gliomaassociated oncogene (Gli) signaling induced by hedgehog proteins (three mammalian homologues: Desert, Indian and Sonic hedgehog), the nature and mode of action of the endogenous ligand and the mechanisms of receptor activation are not fully understood (Byrne et al., 2016; Schulte & Kozielewicz, 2019) . It is known that hedgehog proteins bind Patched, a cholesterol transporter, which in turn regulates SMO activation by postulated regulation of cholesterol levels .
Cholesterol and other naturally occurring sterols are positive allosteric modulators and agonists of SMO in Gli-and G protein-dependent signaling (Nachtergaele et al., 2012; Qi, Liu, Thompson, McDonald, Zhang & Li, 2019; Raleigh et al., 2018; Sever et al., 2016) . Due to the distinct link to human cancer and occurrence of several cancerassociated SMO mutations (e.g. D473H 6.54 or W535L 7.55 ; superscript numbering refers to Ballesteros Weinstein nomenclature of GPCRs (Ballesteros & Weinstein, 1995) ), a plethora of small ligandsantagonists and inverse agonistshave been developed to target this receptor (Wu, Zhang, Sun, McMahon & Wang, 2017) . Two of these compoundsvismodegib and sonidegib -are approved as drugs for the treatment of basal-cell carcinoma (Chen, 2016) . In addition, nature provides an effective SMO antagonist, the plant alkaloid cyclopamine (Incardona, Gaffield, Kapur & Roelink, 1998; Taipale et al., 2000) .
These and other ligands, such as SMO agonists (e. g. SAG1.3, purmorphamine), neutral antagonists (e. g. cyclopamine, SANT-1) or inverse agonists (e. g. cyclopamine-KAAD), are frequently used to explore SMO pharmacology (Chen, 2016; Chen, Taipale, Young, Maiti & Beachy, 2002; Rominger et al., 2009) . To date, binding affinities of these compounds were determined using classical radioligand binding methods (Frank-Kamenetsky et al., 2002; Rominger et al., 2009; Wang et al., 2014) and, more often, fluorescence-based assays using for example the greenyellow fluorescent BODIPY-cyclopamine (Chen, Taipale, Cooper & Beachy, 2002; Chen, Taipale, Young, Maiti & Beachy, 2002; Gorojankina et al., 2013; Huang et al., 2016; Huang et al., 2018; Manetti et al., 2010) . The fluorescently-labelled cyclopamine has been used in three separate experimental approaches: assessment of ligand-receptor interaction based on detection of fluorescence using confocal microscopy, flow cytometry or fluorescence polarization (Bee et al., 2012; Chen, Taipale, Cooper & Beachy, 2002; Chen, Taipale, Young, Maiti & Beachy, 2002; Gorojankina et al., 2013; Huang et al., 2016; Huang et al., 2018) . While these methods offer valuable insight into ligand-receptor binding in live cells, they suffer from several shortcomings, including: 1) laborious protocols that require long ligand incubation times (up to 4-5 hours), 2) extensive cell washing due to lipophilicity of BODIPY-cyclopamine, 3) high levels of non-specific binding in untransfected cells or in the presence of saturating concentrations of unlabeled competitors and 4) the need for data normalization of BODIPY-fluorescence values to receptor expression values.
In order to overcome these experimental limitations, we established and validated a live-cell, nanoluciferase bioluminescence resonance energy transfer (NanoBRET)based binding assay to assess the binding properties of BODIPY-cyclopamine and unlabeled SMO ligands to an N-terminally Nanoluciferase (Nluc)-tagged SMO and CRD SMO in HEK293 cells devoid of endogenous SMO. This proximity-based ligand-binding assay has recently been developed to assess ligand binding to Class A GPCRs and receptor tyrosine kinases (Bosma et al., 2019; Bouzo-Lorenzo et al., 2019; Mocking, Verweij, Vischer & Leurs, 2018; Stoddart et al., 2015; Stoddart, Kilpatrick & Hill, 2018; Sykes, Stoddart, Kilpatrick & Hill, 2019) .
It relies on the high specificity of BRET between Nluc-tagged protein (BRET donor) and fluorescently-tagged ligand (BRET acceptor) that can only occur when both BRET partners are within a distance of 10 nm (100 Å). Thus, the interference of nonspecifically bound probe, outside of the BRET radius to the receptor isin contrast to detecting solely ligand fluorescenceminimal. In the present study, we employ NanoBRET to monitor binding of commercially available SMO ligands. Furthermore, the sensitivity of the assay enables us to dissect the pharmacological properties of separate cyclopamine binding sites in the transmembrane-spanning receptor core of the Class F receptor SMO. Thus, this NanoBRET-based binding assay provides a valuable complement to the toolbox of high-throughput compatible screening assays for Class F GPCRs.
METHODS

Cell culture
SMO HEK293 cells were generated and characterized as described elsewhere (Kozielewicz et al., 2019, submitted) . The cells were cultured in DMEM (HyClone) supplemented with 10% FBS, 1% penicillin/streptomycin, and 1% L-glutamine (all Thermo Fisher Scientific) in a humidified CO2 incubator at 37 °C. All cell culture plastics were from Sarstedt, unless otherwise specified.
DNA cloning and mutagenesis
Nluc-A3 was from Stephen Hill, University of Nottingham, UK (Stoddart et al., 2015) .
SMO-Rluc8 coding for mouse Smoothened was from Nevin A. Lambert, Augusta
University, Georgia, Canada (Wright et al., 2019) . The mouse SMO sequence was subcloned into an empty N-terminally tagged Nluc vector containing 5-HT3A signal peptide using BamHI and XbaI restriction sites. First, the BamHI site present in mouse SMO was removed using site-directed mutagenesis (GeneArt, Thermo Fisher Scientific) with the following primers: 5'-CCTCCAGGGGCTGGGGTCCATTCATTCCCGC-3' (forward primer) and 5'-GCGGGAATGAATGGACCCCAGCCCCTGGAGG-3' (reverse primer). Next, the mouse SMO sequence was cloned in-frame into the Nluc vector using forward primer: 5'-GAC GGA TCC GCG GCC TTG AGC GGG AAC GTG-3' and reverse primer: 5'-CGT TCT AGA TCA GAA GTC CGA GTC TGC ATC-3' . CRD Nluc-SMO was generated using the mouse SMO lacking the BamHI site by cloning it into Nterminally tagged Nluc vector between BamHI and XbaI using forward primer: 5'-GAC GGA TCC GAG GTA CAA AAC ATC AAG TTC-3; and reverse primer: 5'-CGT TCT AGA TCA GAA GTC CGA GTC TGC ATC-3' . CRD and full-length Nluc-SMO D477G 6.54 /E522K 7.38 were generated with site-directed mutagenesis (GeneArt, Thermo Fisher Scientific) by first obtaining D477G 6.54 mutation with the following primers: 5'-GCTGCCACTTCTATGGCTTCTTCAACCAGGC-3' (forward primer) and 5'-GCCTGGTTGAAGAAGCCATAGAAGTGGCAGC-3' (reverse primer).
Subsequently the E522K 7.38 mutation was introduced with 5'-CCCAGCCTCCTGGTGAAGAAGATCAATCTAT-3' (forward primer) and 5'-ATAGATTGATCTTCTTCACCAGGAGGCTGGG-3 (reverse primer). All constructs were validated by sequencing (Eurofins GATC, Konstanz, Germany).
Live-cell ELISA
For quantification of cell surface receptor expression by labelling with anti-Nluc antibody, SMO HEK293 cells at the density of 4·10 5 cells ml -1 were transfected in suspension using Lipofectamine 2000 with 50-500 ng of the indicated receptor plasmid DNA with 500-950 ng of pcDNA plasmid DNA. The cells (100 µl) were seeded onto a PDL-coated transparent 96-well plate with flat bottom and grown overnight. 24 hr later the cells were washed twice with 0.5% BSA in PBS and incubated with a rabbit anti-Nluc (2 µg·ml -1 ; RnD Systems #MAB10026) in 1% BSA/PBS for 1 hr at 4°C. Following incubation, the cells were washed four times with 0.5% BSA/PBS and incubated with a horseradish peroxidase-conjugated goat antirabbit antibody (1:3,000; Thermo Fisher Scientific #31460) in 1% BSA/PBS for 1 hr at 4°C. The cells were washed three times with 0.5% BSA/PBS, and 50 µl of the peroxidase substrate TMB (3,3',5,5'-tetramethylbenzidine; Sigma-Aldrich #T8665)
were added. The cells were further incubated for 20 minutes and upon development of a blue product, 50 µl of 2 M HCl were added and the absorbance was read at 450 nm using a BMG  POLARstar plate reader. The data were analyzed in GraphPad Prism 6.
Immunoblotting
SMO HEK293 cells were transfected in suspension using Lipofectamine 2000 (50-500 of receptor plasmid DNA with 500-950 ng of pcDNA plasmid DNA per 4·10 5 cells ml -1 ) and seeded (700 µl) onto wells of a 24-well plate. Protein lysates were obtained using Laemmli buffer with 0.5% NP-40 and 5% β-mercaptoethanol. Lysates were sonicated and analyzed on 4-20 % Mini-PROTEAN TGX precast polyacrylamide gels (Bio-Rad) and transferred to PVDF membranes using the Trans-Blot Turbo system (Bio-Rad). After blocking with 5% milk in TBS-T, membranes were incubated with primary antibodies in blocking buffer: rabbit anti-GAPDH (1:5000; Cell Signaling Technology #2118) and mouse anti-Nluc (0.5 µg·ml -1 ; RnD Systems #MAB10026), overnight at 4 °C. Proteins were detected with horseradish peroxidase-conjugated secondary antibody (1:5,000; goat anti-rabbit (Thermo Fisher Scientific #31460 or 1:3,000; goat anti-mouse; Thermo Fisher Scientific #31430) and Clarity Western ECL Blotting Substrate (Bio-Rad).
NanoBRET binding assay
SMO HEK293 cells were transiently transfected in suspension using Lipofectamine To analyze the labelled ligand binding kinetics data, one-phase association or twophase association models were selected based on an extra-sum-of square F-test:
One-phase association:
Two-phase association:
Where: Y0 is Y value at time x = 0, plateau is the Y value at infinite times and kobs is the association constant expressed in 1 , t1/2 = ln(2)/kobs
Given the observed complexity of BODIPY-cyclopamine binding at different concentrations, herein we present the raw values from kinetics experiments for each concentrations at the tested SMO constructs.
Materials
BODIPY-cyclopamine was from BioVision Inc. Purmorphamine (9-Cyclohexyl-N-[4-
Cyclopamine-KAAD and SANT-1 ((4-Benzyl-piperazin-1-yl)-(3,5-dimethyl-1-phenyl-1H-pyrazol-4-ylmethylene)-amine) were from Abcam. All ligands were dissolved in DMSO and stored in aliquots at -20°C. The ligands underwent a maximum of 2 freeze-thaw cycles. Colenterazine h was from Biosynth and it was stored as 2.4 mM aliquots in acidified ethanol at -80°C. Protein-low binding tubes (Eppendorf) were used to make serial dilutions of BODIPY-cyclopamine.
RESULTS
N-terminally Nluc tagged SMO constructs are expressed at the cell surface
In order to establish a NanoBRET-based binding assay for the Class F receptor SMO, we adopted the cloning strategy of previously presented Class A GPCR including a 5-HT3A receptor-derived signal sequence and an extracellular, Nterminally Nluc fused to either the full length mouse SMO or SMO lacking the extracellular cysteine-rich domain (CRD). Subsequently, these constructs are referred to as Nluc-SMO and CRD Nluc-SMO, respectively ( Fig. 1a) . Both receptor constructs are expressed in the cells and at the cell surface upon transient transfection of SMO HEK293 cells as shown by immunoblotting of whole cell lysates and a live-cell surface ELISA (Fig. 1a, b ).
BODIPY-cyclopamine binding to Nluc-SMO can be monitored by NanoBRET
The commercially available, BODIPY-labelled derivative of the plant alkaloid cyclopamine (BODIPY-cyclopamine; Fig. 2a ) associates with Nluc-SMO transiently expressed in SMO HEK293 cells in a concentration-dependent manner reaching saturation at ~1000 nM (one-site fit Kd = 170.9 ± 26.6 nM, Fig. 2b, c) . Similarly, BODIPY-cyclopamine binds the SMO construct lacking the CRD (two-sites fit Kd1 = 4.0 ± 0.9 nM, Fig. 2d,e) . The BODIPY-cyclopamine bound CRD Nluc-SMO with higher affinity and importantly the NanoBRET produced by BODIPY-cyclopamine binding was larger in the CRD Nluc-SMO compared to Nluc-SMO (two-sites fit BRET Bmax1 CRD receptor = 0.08 ± 0.01 and one-site fit BRET Bmax full-length receptor = 0.034 ± 0.001). Furthermore, BODIPY-cyclopamine binding to CRD Nluc-SMO was more complex than binding to Nluc-SMO as indicated by the multiphasic binding curve for CRD Nluc-SMO especially at higher concentrations of the ligand (two-sites fit Kd2 = 371.3 ± 266.1 nM) . While quantification of BODIPYcyclopamine binding on living cells was assessed 60 min after ligand addition, we were also interested in the binding kinetics of BODIPY-cyclopamine. Therefore, we followed BODIPY-cyclopamine association at different ligand concentrations using
Nluc-SMO and CRD Nluc-SMO expressing SMO HEK293 cells ( Fig. 3a,b) . First, the kinetic analysis confirmed that saturation was reached at 60 min ligand exposure as used for experiments presented in Moreover, the analysis also showed a substantial difference in t1/2 of BODIPYcyclopamine at both receptors ( Table 1 and 2). In order to further dissect BODIPYcyclopamine association to SMO we employed the SMO antagonist SANT-1 at 10 µM, which interacts with the 7TM core of the receptor (Chen, Taipale, Young, Maiti & Beachy, 2002) . For both receptor constructs SANT-1 reduced association of BODIPY-cyclopamine at the two lower concentrations but did not completely abrogate binding of 1000 nM BODIPY-cyclopamine. (Fig.   4a,b) . This was particularly obvious when comparing the fluorescence signal at a BODIPY-concentration producing maximal binding in the absence and presence of 10 µM SANT-1 for the Nluc-SMO and the CRD Nluc-SMO constructs (Fig. 4c) . At this concentration the NanoBRET signal was blocked by SANT-1, whereas fluorescence was not affected.
NanoBRET
BODIPY-cyclopamine binding to SMO is surmountable
To explore the competitive nature of BODIPY-cyclopamine binding to SMO in more Fig. 5a, Table 1) . A similar rank order was obtained in the CRD Nluc-SMOtransfected cells (Fig. 5b, Table 2 ). Interestingly, residual BODIPY-cyclopamine binding produced NanoBRET, at competitor concentrations sufficiently high to reach saturation, that were substantially higher in the full length Nluc-SMO compared (Fig.   5a ) to CRD Nluc-SMO ( Fig. 5b) . At maximal competition SANT-1 reduced BODIPYcyclopamine (200 nM) binding to 45.2% of maximal binding, whereas it completely abolished BODIPY-cyclopamine (10 nM) binding at the CRD Nluc-SMO (~0.1% binding left). These findings indicate that, at the tested concentrations, BODIPYcyclopamine binding is surmountable to a higher degree at the CRD Nluc-SMO compared to Nluc-SMO. Additionally, cyclopamine-KAAD competition with BODIPYcyclopamine at the full-length receptor did not reach the plateau indicating further displacement of the fluorescent ligand, presumably at a different binding pocket.
Differential competition of BODIPY-cyclopamine binding allows pharmacological separation of two binding sites
The successful targeting of SMO with vismodegib in the therapy of basal cell carcinoma has also led to the discovery of therapy-resistant point mutations in SMO (Zhang, Sun, Liu & Song, 2018) . Here, we introduced the double mutant D477G 6.54 /E522K 7.38 into Nluc-SMO and CRD Nluc-SMO (corresponding to human D473 6.54 and E518 7.38 mutants) in order to further dissect the contribution of different binding sites to BODIPY-cyclopamine-SMO interaction. The mutant versions are expressed on the cell surface upon transient transfection in DSMO HEK293 cells ( Fig. 6a) . In order to further define the binding characteristics of the two separate BODIPY-cyclopamine binding sites in the 7TM core of the receptor, we made use of a saturating concentration of SANT-1 (10 µM) and probed the wild type and D477G 6.54 /E522K 7.38 of Nluc-SMO and CRD Nluc-SMO with increasing concentrations of BODIPY-cyclopamine (Fig. 6b, c) . In line with the competition data using a fixed BODIPY-cyclopamine concentration, we found that SANT-1, which solely binds to the 7TM ligand binding site of SMO SANT-1 (10 µM), which targets the lower binding pocket, maintains its effect on BODIPY-cyclopamine at both the wt and the D477G 6.54 /E522K 7.38 for full length and CRD SMO. Importantly, the double mutant does not affect the SANT-1-insensitive fraction of BODIPY-cyclopamine binding in CRD Nluc-SMO (Fig. 6c) . In addition, we provide a kinetics analysis of BODIPY-cyclopamine association to D477G 6.54 /E522K 7.38 CRD Nluc-SMO ( Fig. 6d; Table 5 ). At 1000 nM BODIPYcyclopamine the t1/2 and kobs of the D477G 6.54 /E522K 7.38 CRD Nluc-SMO are very similar to Nluc-SMO, suggesting binding to the same ligand binding site.
DISCUSSION
The development of a NanoBRET-based ligand binding assay provides an interesting complement to GPCR pharmacology enabling ligand binding studies on living cells in real time with simplified protocols (Stoddart et al., 2015; Stoddart, Kilpatrick & Hill, 2018 Recent insight into the molecular mechanisms of drug action on SMO by crystallography and CryoEM provide somewhat controversial yet intriguing information regarding cyclopamine and cholesterol interaction with the 7TM ligandbinding site and the CRD (Deshpande et al., 2019; Huang et al., 2016; Huang et al., 2018; Qi, Liu, Thompson, McDonald, Zhang & Li, 2019; Weierstall et al., 2014) . Here, we have been able to pharmacologically separate two BODIPY-cyclopamine binding sites on the 7TM core of SMO. Total BODIPY-cyclopamine binding to full length Nluc-SMO is composed of at least two components: ligand binding to the CRD (Huang et al., 2016; Huang et al., 2018 )for which we did not find evidence for in our experimentsand the 7TM core (Huang et al., 2018; Weierstall et al., 2014) . Most importantly, SANT-1, which solely binds to the receptor core in the lower pocket of the SMO binding site , competes with BODIPY-cyclopamine more efficiently in the CRD Nluc-SMO compared to the full length receptor. This large increase in affinity and NanoBRET signal/Bmax suggest that the CRD exerts a negative allosteric modulation on BODIPY-cyclopamine binding to the SMO 7TM core. The residual binding of BODIPY-cyclopamine to CRD Nluc-SMO above 10 -7 M identifies a SANT-1-insensitive fraction suggesting an additional binding pocket for BODIPY-cyclopamine. Given the simultaneous binding of SAG21k and cholesterol to SMO in the recent crystal structure (PDB 6O3C) of active, nanobody NbSmo8-bound SMO (Deshpande et al., 2019) , and the fact that SANT-1 and cyclopamine occupy two different parts of the small molecule binding space in SMO (Huang et al., 2018; Wang et al., 2014; Weierstall et al., 2014) it could also be possible that BODIPYcyclopamine and SANT-1 bind the 7TM course simultaneously. It remains to be verified by structural studies if binding modes of cyclopamine and BODIPYcyclopamine are indeed the same. Along these lines, different binding poses of cyclopamine and related sterols were reported in several crystal structures using SMO from various species. In summary, there is a cyclopamine/sterol binding site in the lipid groove of the CRD (Byrne et al., 2016; Deshpande et al., 2019; Huang et al., 2016; Huang et al., 2018) , one in the upper pocket of the 7TM core (Huang et al., 2018; Qi, Liu, Thompson, McDonald, Zhang & Li, 2019) and one in the lower position (Deshpande et al., 2019) , which overlaps with the SANT-1 binding pocket (Fig. 7) . Moreover, SAG1.3-induced Gli transcriptional activity still reaches saturation albeit at lower efficacy following treatment with SANT-1.This further provides functional evidence that both the upper (SAG1.3 binding site) and the lower pocket (SANT-1 binding site) in the 7TM core of SMO can be occupied by ligands simultaneously and that these pockets may allosterically regulate each other (Chen, Taipale, Young, Maiti & Beachy, 2002) . Similar conclusions were drawn from radioligand binding studies (Frank-Kamenetsky et al., 2002; Tao et al., 2011) .
Furthermore, the phenomenon of allosteric regulation in the SMO binding site was also inferred from studies on other SMO ligands Hoch et al., 2015) .
Interestingly, removal of the CRD of SMO increased both Bmax and the Kd of BODIPY-cyclopamine. The absence of the CRD, which obviously includes extinction of the proposed CRD binding site for BODIPY-cyclopamine, most likely provides better access to the normally buried binding site in the core of the receptor causing a left shift and an increased Bmax. Related to that, one might also postulate an allosteric action of the CRD on the ligand-binding site on the 7TM core, an idea that is fueled by the observation that CRD SMO exerts a higher constitutive activity (Byrne et al., 2016) . A part of the explanation for the efficacy shift of the BODIPY-cyclopamine binding curve could also be the altered BRET parameters since the distance of the NanoBRET donor and the acceptor are likely shorter in the CRD SMO compared to the full length receptor. However, while the different BRET efficiencies in the two receptor constructs could affect the amplitude of the NanoBRET signal originating from BODIPY-cyclopamine binding, it cannot explain the leftward shift of the binding curves indicating a higher affinity to the CRD Nluc-SMO. It should be noted that in previous publications low concentrations of BODIPY-cyclopamine (usually 5 nM)
were used for SMO binding assays. Given our data regarding the different affinities of the separate BODIPY-cyclopamine binding sites, these low ligand concentrations neither allowed sampling the SANT-1-insensitive, low affinity site in the core of CRD-Nluc SMO nor the putative site on the CRD of the full-length receptor.
Application of the novel NanoBRET methodology, however, allows to reliably detect even picomolar and nanomolar amounts of BODIPY-cyclopamine bound to CRD Nluc-SMO and CRD Nluc-SMO D477G 6.54 /E522K 7.38 .
In summary, we dissect BODIPY-cyclopamine interaction with two binding sites on the 7TM core with different affinities. The high affinity site is the deep SANT-1 binding pocket. Since the D477G 6.54 /E522K 7.38 in TM6 and TM7 partially affect the high affinity component of BODIPY-cyclopamine binding, it could be that interaction with D477 6.54 /E522 7.38 provides a transition mechanism of ligand binding to the deeper pocket. Low affinity binding to the D477G 6.54 /E522K 7.38 mutant in the upper 7TM site is still possible and that binding is insensitive to allosteric modulation by SANT-1 binding to the deeper site.
For drug discovery efforts, the CRD Nluc-SMO probe presents a valuable tool with an advantageous assay window. The intrinsic caveat of the lack of the physiologically relevant CRD, however, remains, requiring thorough validation of screening hits in assays relying on full length SMO. Further work will address in which way the separate ligand-binding sites interact allosterically and what role the CRD-core contacts play for that potential communication.
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